Evidence map›Paper›PMID 28676824›Full record

ArticleInternational journal of endocrinology2017

Prognostic Impact of miR-224 and RAS Mutations in Medullary Thyroid Carcinoma.

Elisabetta Cavedon, Susi Barollo, Loris Bertazza, Gianmaria Pennelli, Francesca Galuppini, Sara Watutantrige-Fernando, Simona Censi, Maurizio Iacobone, Clara Benna, Federica Vianello and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of endocrinology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Grading of medullary thyroid carcinoma on the basis of tumor necrosis and high mitotic rate is an independent predictor of poor outcome.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2020
    Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Elisabetta CavedonFamilial Tumor Unit, Veneto Institute of Oncology, (IOV)-IRCCS, Padova, Italy.ORCID 0000-0002-9075-6033
Susi BarolloEndocrinology Unit, Department of Medicine (DIMED), University of Padua, Padua, Italy.
Loris BertazzaEndocrinology Unit, Department of Medicine (DIMED), University of Padua, Padua, Italy.
Gianmaria PennelliSurgical Pathology & Cytopathology Unit, Department of Medicine (DIMED), University of Padua, Padua, Italy.
Francesca GaluppiniSurgical Pathology & Cytopathology Unit, Department of Medicine (DIMED), University of Padua, Padua, Italy.
Sara Watutantrige-FernandoEndocrinology Unit, Department of Medicine (DIMED), University of Padua, Padua, Italy.
Simona CensiEndocrinology Unit, Department of Medicine (DIMED), University of Padua, Padua, Italy.
Maurizio IacoboneSurgery Unit, Department of Surgical, Oncological and Gastroenterological Sciences (DISCOG), University of Padua, Padua, Italy.
Clara BennaSurgery Unit, Department of Surgical, Oncological and Gastroenterological Sciences (DISCOG), University of Padua, Padua, Italy.
Federica VianelloDepartment of Radiotherapy, Veneto Institute of Oncology (IOV)-IRCCS, Padova, Italy.
Stefania ZovatoFamilial Tumor Unit, Veneto Institute of Oncology, (IOV)-IRCCS, Padova, Italy.
Davide NacamulliEndocrinology Unit, Department of Medicine (DIMED), University of Padua, Padua, Italy.
Caterina MianEndocrinology Unit, Department of Medicine (DIMED), University of Padua, Padua, Italy.
University of Padua · ITIstituto Oncologico Veneto · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Little is known about the function of microRNA-224 (miR-224) in medullary thyroid cancer (MTC). This study investigated the role of miR-224 expression in MTC and correlated it with mutation status in sporadic MTCs. A consecutive series of 134 MTCs were considered. Patients had a sporadic form in 80% of cases (107/134). In this group, REarranged during transfection (

Identifiers

PMID28676824
PMCPMC5476902
OpenAlexW2621439154

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.